Colgate-Palmolive Company Company Profile (NYSE:CL)

Colgate-Palmolive Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "CL."

Colgate-Palmolive Company declared a quarterly dividend on Thursday, June 8th. Investors of record on Tuesday, July 18th will be paid a dividend of $0.40 per share on Tuesday, August 15th. This represents a $1.60 dividend on an annualized basis and a yield of 2.11%. The ex-dividend date is Friday, July 14th. View Colgate-Palmolive Company's Dividend History.

Colgate-Palmolive Company (NYSE:CL) announced its quarterly earnings data on Friday, April, 28th. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analysts' expectations of $3.80 billion. Colgate-Palmolive Company had a return on equity of 3,725.55% and a net margin of 16.31%. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the business posted $0.63 earnings per share. View Colgate-Palmolive Company's Earnings History.

Colgate-Palmolive Company is scheduled to release their next quarterly earnings announcement on Friday, July, 21st 2017. View Earnings Estimates for Colgate-Palmolive Company.

14 equities research analysts have issued 12 month price objectives for Colgate-Palmolive Company's shares. Their forecasts range from $68.00 to $80.00. On average, they expect Colgate-Palmolive Company's stock price to reach $74.75 in the next year. View Analyst Ratings for Colgate-Palmolive Company.

Here are some recent quotes from research analysts about Colgate-Palmolive Company stock:

• 1. Jefferies Group LLC analysts commented, "Late Tues. (5/16), the NY Post reported that CL Chair/CEO Ian Cook recently told investors he would consider selling the company for $100/share (~19.5x EV/EBITDA). While we have no knowledge of any potential M&A or the specific accuracy of this report, this strikes us as a reasonable price (for both a potential buyer and for CL as sellers). We view JNJ as the most likely acquirer, followed by ULVR and KHC/3G. Valuation remains nearly full, reit. $76 PT, Hold. CL CEO/Chairman Ian Cook reportedly would consider selling for $100/share: Late Tuesday, the NY Post reported the Ian Cook, Colgate’s Chairman and CEO, recently signaled he would be open to selling the company… for $100/share", while at a meeting with institutional investors. The Post further noted recent speculation the CL is being stalked by" Unilever and pointed to activist Nelson Peltz’s stake in P&G as a potential spark for sector consolidation." (5/17/2017)
• 2. According to Zacks Investment Research, "After posting in-line earnings for two straight quarters, Colgate delivered a positive earnings surprise in first-quarter 2017. Also, the bottom line grew year over year, aided by margin expansion and lower tax rate. The company has been witnessing enhanced margins for a while now, driven by the cost-savings from the funding-the-growth and 2012 Restructuring Program. Also, better pricing and emerging market growth boosted its performance amid a tough macro environment. However, Colgate has underperformed the broader industry in the last six months, mainly due to its soft sales trend. The company lagged sales estimates in 15 out of the past 16 quarters, largely hurt by currency woes. Management expects adverse currency and a tough global environment to impact 2017 results, as reflected by its outlook. Nonetheless, organic sales are expected to improve sequentially throughout the year. Also, Colgate’s shareholder-friendly moves are noteworthy." (5/3/2017)
• 3. B. Riley analysts commented, "Colgate (CL) reported 4Q16 EPS of $0.75 vs. $0.73, in line with consensus and $0.01 below our estimate. Op. profit of $1,038MM (+2% YoY) fell short of consensus of $1,071MM. Organic sales were +1.5% (+4.6% exp.), with organic volume -1%'this was only the second quarter since 2002 with an organic volume decline for CL. Volume was impacted by the India demonetization and a distributor issue in Africa/ Eurasia; organic volume was up in only one of the six segments. CL expects organic sales +4% in 2017, and cut EPS guidance from up double-digits to up low-single digits, due to FX and lower category growth rates. We are lowering our 2017E/2018E EPS by $0.20 each to $2.90/$3.20 and our PT from $78.00 to $74.00, based on 23x 2018E EPS of $3.20. While 3% EPS growth in 2017 looks achievable (even conservative), we are concerned by how much marketing investment, and competitive 'catching up,' is implied. If interest rates go higher in 2017, staples stocks may have a tough time outperforming, but we view Procter & Gamble (PG; Buy; $106.00 PT) as more attractive than CL, because PG's organic sales growth is driving higher toward 3%, while CL's has been decelerating. As the gap continues to narrow between CL's and PG's organic sales growth rates, we think investors will become increasingly attracted to PG. The two stocks' valuations are similar on EV-to-EBITDA." (1/29/2017)
• 4. Berenberg Bank analysts commented, "Colgate has an enviable position in oral care..: Nearly half of Colgate's sales are in oral care, a category in which the growth outlook remains robust, and high consolidation/low innovation requirements facilitate profitable growth. Its second-largest category, pet nutrition, also has attractive characteristics; however, the rest of HPC is less appealing."'Although not enough to sustain its top-line growth premium: Colgate's growth premium has faded, disappearing in 2016 as market share gains eased and organic growth slowed to 4%. Before 2010, over a third of Colgate's growth came from outperformance whereas in aggregate its market share has not changed since 2010. While we expect organic growth to improve (to 5% in 2017E-19E), helped by a step-up in innovation, it will remain below history and at only a small premium to peers. High existing market shares, particularly in oral care, will inhibit further share gains." (1/25/2017)

Some companies that are related to Colgate-Palmolive Company include Unilever plc (ULVR), Estee Lauder Companies, Inc. (The) (EL), Herbalife LTD. (HLF), Energizer Holdings (EPC), Nu Skin Enterprises (NUS), Avon Products (AVP), USANA Health Sciences (USNA), PZ Cussons plc (PZC), Nautilus Group, Inc. (The) (NLS), Swallowfield plc (SWL) and Litebulb Group Ltd (LBB).

Colgate-Palmolive Company's management team includes the folowing people:

• Ian M. Cook, Chairman of the Board, President, Chief Executive Officer
• Daniel B. Marsili, Chief Human Resource Officer
• John J. Huston, Senior Vice President - Chief of Staff
• Patricia Verduin Ph.D., Chief Technology Officer
• Mukul V. Deoras, Chief Marketing Officer
• Victoria L. Dolan, Chief Transformation Officer, Corporate Controller
• Delia H. Thompson, Chief Investor Relations Officer
• Makarand Karnataki, Company Secretary and Compliance Officer
• Jennifer M. Daniels, Chief Legal Officer and Secretary
• Charles A. Bancroft, Independent Director

Colgate-Palmolive Company's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.50%), State Street Corp (6.86%), BlackRock Inc. (5.81%), FMR LLC (3.72%), Massachusetts Financial Services Co. MA (3.33%) and Bank of New York Mellon Corp (2.13%). Company insiders that own Colgate-Palmolive Company stock include Daniel B Marsili, Delano E Lewis, Delia H Thompson, Dennis J Hickey, Ellen M Hancock, Fabian T Garcia, Franck J Moison, Ian M Cook, Jennifer Daniels, John J Huston, John T Cahill, Justin Skala, Mukul Deoras, Noel R Wallace, Patricia Verduin, Richard J Kogan, Stephen I Sadove and Victoria L Dolan. View Institutional Ownership Trends for Colgate-Palmolive Company.

Colgate-Palmolive Company's stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, Prudential Financial Inc., Renaissance Technologies LLC, Alecta Pensionsforsakring Omsesidigt, Janus Capital Management LLC, Sustainable Growth Advisers LP and Investec Asset Management LTD. Company insiders that have sold Colgate-Palmolive Company stock in the last year include Daniel B Marsili, Ellen M Hancock, Franck J Moison, Jennifer Daniels, John J Huston, Noel R Wallace, Patricia Verduin, Richard J Kogan and Stephen I Sadove. View Insider Buying and Selling for Colgate-Palmolive Company.

Colgate-Palmolive Company's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., TIAA CREF Investment Management LLC, Massachusetts Financial Services Co. MA, Marshall Wace North America L.P., Swiss National Bank, Loomis Sayles & Co. L P and Geode Capital Management LLC. View Insider Buying and Selling for Colgate-Palmolive Company.

Shares of Colgate-Palmolive Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Colgate-Palmolive Company stock can currently be purchased for approximately $75.89.